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Abstract: Potent drugs are desperately needed to counteract bacterial biofilm infections, 
especially those caused by gram-positive organisms, such as Staphylococcus aureus. 
Moreover, anti-biofilm compounds/agents that can be used as chemical tools are also 
needed for basic in vitro or in vivo studies aimed at exploring biofilms behavior and 
functionability. In this contribution, a collection of naturally-occurring abietane-type 
diterpenes and their derivatives was tested against S. aureus biofilms using a platform 
consisting of two phenotypic assays that have been previously published by our group. 
Three active compounds were identified: nordehydroabietylamine (1), (+)-dehydroabietic 
acid (2) and (+)-dehydroabietylamine (3) that prevented biofilm formation in the low 
micromolar range, and unlike typical antibiotics, only 2 to 4-fold higher concentrations 
were needed to significantly reduce viability and biomass of existing biofilms. Compound 
2, (+)-dehydroabietic acid, was the most selective towards biofilm bacteria, achieving high 
killing efficacy (based on log Reduction values) and it was best tolerated by three different 
mammalian cell lines. Since (+)-dehydroabietic acid is an easily available compound, it 
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holds great potential to be used as a molecular probe in biofilms-related studies as well as 
to serve as inspirational chemical model for the development of potent drug candidates. 
Keywords: anti-biofilm; inhibitor; biofilm; Staphylococcus aureus; abietic acid; natural 
compounds; phenotypic assays; (+)-dehydroabietic acid; screening 
 
1. Introduction 
Bacterial biofilms is the term used to describe the surface-attached bacterial lifestyle. Cells in 
biofilms grow as communities, surrounded by a self-produced thick layer of extracellular polymeric 
substances (EPS, also known as matrix or slime). Thus, biofilms are structurally different from  
single-cells (planktonic) bacteria. These differences in the physical architecture between biofilms and 
single-cell bacteria also relate to their differences in functional behavior. The presence of the matrix, 
for instance, protects cells in biofilms from the detrimental effects of chemical insults. In fact, due to 
the presence of the matrix as well as slower growth rate and resistant subpopulations, biofilms possess 
much lower susceptibility to antimicrobial therapy or biocides [1–3].  
Biofilms are involved in a wide range of infections such as periodontitis, otitis, cystic fibrosis, 
urinary tract infections, osteomyelitis and medical device-associated infections, and they account for 
an overwhelming proportion of the persistent, antibiotic-resistant infections [4,5]. Because the 
resistance mechanisms in biofilms are of multifactorial nature, drug discovery efforts need to be 
guided in various directions. Methodology-wise, the search for anti-biofilm compounds has been 
embraced by using target-directed, phenotypic-based as well as in silico approaches (for a recent 
review see [6]). Using small molecular weight compounds that can easily penetrate the biofilms 
without significant chemical degradation is still a largely pursued strategy, on the rationale that such 
compounds can decrease the burden of viable cells, and/or sensitize biofilms to conventional  
anti-biofilm therapy. However, so far, still a limited repertoire of easily available compounds has been 
reported that can selectively act in vitro and eradicate existing biofilms at low concentrations, 
especially in the case of those formed by Staphyloccocus aureus [7]. Moreover, only one disinfectant 
(commercially sold by Sterilex, a US-based company) and no antibiotic has been approved by a 
regulatory agency, to use specifically against bacterial biofilms. Lacking of potent controls is also a 
common scenario in basic biofilm studies, since even millimolar concentrations of antibiotics are not 
enough to cause high inhibitory effects [1,8]. Thus, from a basic research perspective, the limited 
repertoire of active compounds that can be used as chemical tools or probes limits target validation 
studies, as well as in vitro or in vivo studies aimed at exploring biofilms behavior and functionality. 
From a drug discovery viewpoint, the lacking of drug candidates places us in a very vulnerable 
position to face infectious diseases. Thus, expanding antibacterial discovery to the search for new  
anti-biofilm compounds seems mandatory for current pharmaceutical and biomedical research.  
One of the major defenses of coniferous plants is the secretion of oleoresin, which is a complex 
mixture of terpenoids consisting of turpentine (monoterpene and sesquiterpene) and rosin (diterpene) 
fractions. If the plant is injured, the turpentine acts as the solvent that transports compounds from the 
rosin fraction to the damaged site. Once exposed to atmospheric conditions, the volatile turpentine 
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evaporates leaving the diterpenoid resin acids. The resin acids polymerize to form a chemical barrier 
that seals the wound while trapping insect invaders and microbial pathogens [9]. A complex mixture of 
diterpenoid resin acids is obtained in bulk quantities from industrial manufacture of cellulose using the 
Kraft process, and various resin acid mixtures are commercially available. In addition, the resin acids 
can be obtained directly from the coniferous rosin. Some representatives of this class of abietane-type 
diterpenoids are abietic acid, neoabietic acid, palustric acid, pimaric acid and isopimaric acid.  
Antibacterial effects of the diterpenoid resin acids have been indeed studied, specifically against 
methicillin-resistant S. aureus strains [10,11] and in particular of abietane-type diterpenes [12]. 
However, the investigation on the anti-biofilm properties of these compounds has been very scarce, 
and only two studies have addressed it, resulting in the identification of two anti-biofilm compounds: 
4-epi-pimaric acid [13] and salvipisone [14]. Thus, although still largely unexplored, it seems likely 
that diterpenoid resin acids compounds can display anti-biofilm properties.  
Here, we attempted to find and characterize compounds acting on S. aureus biofilms from a 
collection of abietane-type diterpenes containing relatively simple resin acids that have not been 
previously studied. These compounds are easily available, chemically stable and cost-effective which 
altogether benefit their wider exploitation as potent anti-biofilm probes in laboratory trials. 
Furthermore, focusing on these compounds allows the revalorization of a previously neglected product 
from the forest industry (wood rosin), which is a desirable strategy towards the discovery of more 
environmentally friendly biocides.  
2. Results and Discussion 
S. aureus is a very versatile pathogen due to its various resistance mechanisms and it is  
frequently associated to hospital-acquired infections, which are often related to biofilms in medical 
devices [15–17]. Promising anti-biofilm compounds have been described, but a recurrent feature of 
these studies is that they typically focus only on preventing staphylococcal attachment. Several 
compounds have been reported to prevent bacterial colonization on different surfaces without killing 
planktonic cells [18–20]. Among them, furanones, a naturally occurring class of compounds, have 
shown ability to prevent bacterial adhesion, which could be related to some extent to their inhibitory 
effects of quorum sensing in Staphylococcus spp. [21]. These compounds could be useful for coating 
medical devices. However, a great need also exists for easily available compounds able to act on 
existing biofilms to counteract the infection once it has been started.  
2.1. Identification of Three Anti-Biofilms Compounds 
In this contribution, 10 abietane-type diterpenes, including the commercially available  
(+)-dehydroabietic acid and (+)-dehydroabietylamine as well as eight other semi-synthetic derivatives 
(Table 1 and the Appendix), were screened for anti-biofilm activity against S. aureus biofilms using a 
screening platform developed by us [8].  
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Table 1. Chemical structures of the abietane-type diterpenes studied in this contribution.  
 
Code R Code R 
1 NH2 6 CH2NHCONH-p-(C6H4)OPh 
2 CO2H 7 CH2NHCONH(C6H3)(3-OPh)(4-Cl) 
3 CH2NH2 8 CH2NHCONH(C6H2)(3,6-OMe)(4-Cl) 
4 CH2NHCONH-p-(C6H4)OBn 9 CH2NHCONH(tert-Bu) 
5 CH2NHCONH-m-(C6H4)Cl 10 CH2NHCONH-5-(benzo-1,3-dioxolyl) 
Abbreviations: Bn, benzyl; Ph, phenyl; Bu, butyl; Me, methyl. 
Table 2. Potencies (IC50 values, expressed in μM and mg/L) for compounds 1–3 measured 
for anti-biofilm as well as antibacterial effects on planktonic S. aureus. Potency curves 
were obtained using at least 14 concentration points, with four replicates per concentration 
in two separate experiments (biological replicates) as described in 4.8. 
 
Effects on biofilms  
IC50, μM [mg/L] (95% confidence intervals) 
Effect on planktonic Bacteria 3 
MIC, μM [mg/L] 
Cpd 
Prior to biofilm formation 1 Post-biofilm formation 2 
Turbidity 
Viability Biomass Viability Biomass 
1 
124.0 [33.7]  
(114.6–134.1) 
115.6 [31.4]  
(105.7–126.5) 
288.4 [78.3] 
(266.2–312.5) 
293.7 [79.7] 
(183.1–471.0)
160 [43.4] 
2 
27.8 [8.35]  
(20.2–38.2) 
33.9 [10.2]  
(23.9–48.3) 
112.8 [33.9] 
(92.9–132.5) 
81.2 [24.4]  
(50.9–129.2) 
70 [21.0] 
3 
28.2 [8.05]  
(26.3–30.2) 
17.4 [33.7]  
(15.5–19.5) 
83.4 [23.8]  
(73.6–94.5) 
74.4 [21.2]  
(70.8–78.2) 
40 [11.4] 
Penicillin 
0.13 [0.048]  
(0.12–0.13) 
0.024 [0.0089] 
(0.02–0.03) 
45.2% a 56.5% a 0.12 [0.045] 
a Percentual inhibition at 5 mM. Penicillin fails to cause more than 57% of biofilm inhibition in the  
post-exposure assay, as previously shown by our group in [8]; 1 Bacterial suspensions and compounds were 
added, and biofilms were formed for 18 h (37 °C, 200 rpm); 2 Biofilms were formed for 18 h (37 °C,  
200 rpm), compounds were then added for 24 h (37 °C, 200 rpm); 3 Bacterial suspensions and compounds 
were incubated for 18 h (37 °C, 200 rpm) prior to MIC measurement. 
Compounds were tested by adding them before biofilms were formed (prior-exposure) or after 
forming them (post-exposure) and effects on viability and biofilm biomass were simultaneously 
measured in both exposure types, using resazurin and crystal violet staining assays, respectively.  
Given the very low rate of positive hits that has been previously detected in our laboratory against this 
strain [22] and in order to increase the chances of identifying hits (even weak ones), we chose to 
perform this initial screening at an unusually high concentration of 400 µM, when compared to the 
concentrations that are used for primary screenings, typically within the low micromolar range  
(1–10 µM). Nordehydroabietylamine (1), (+)-dehydroabietic acid (2), and (+)-dehydroabietylamine (3) 
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were shown to significantly prevent biofilm formation and to act on formed S. aureus biofilms with 
potencies confirmed in the micromolar range (Table 2), whereas none of the urea derivatives (4–10) 
were active. 
Potency values obtained for the three active compounds 1–3 were consistent when measuring their 
effects in biofilm biomass and viability on the two exposure paradigms (Table 2). Anti-biofilm potency 
assessments revealed that positive effects on existing biofilms were displayed at only 2 to  
4 times greater concentrations of the compounds, if compared to the ones needed to prevent biofilms 
establishment. This is an important advantage as opposed to typical antibiotics, for which up to  
1000-fold higher concentrations are needed for eradication of mature biofilms [1,3,23,24]. The order of 
compound activity in both exposure paradigms was: 1 < 2 < 3. 
2.2. Antibacterial versus Anti-Biofilm Effects of Compounds 1–3 
To determine whether the detected effects in prevention of biofilm formation could be at least 
partially related to antibacterial effects on suspended cells, MIC values were calculated (Table 2). 
Although the three compounds were effective against planktonic bacteria, their MIC values were 
higher than those concentrations causing 50% inhibition of biofilm formation, thus indicating that 
preventive effects on biofilm formation can be caused by non-bacteriostatic mechanisms. The best 
selectivity towards S. aureus biofilms was displayed by compound 2, which had a MIC value of 70 μM 
but prevented 50% of biofilm formation (IC50) at 30 µM and reached 90% of biofilms inhibition (IC90) 
at a sub-MIC value of 60 µM. In contrast, 4-epi-pimaric acid was reported to prevent biofilm 
formation by the oral pathogen Streptococcus mutans, at a concentration of 13.2 μM, which was only 
half its MIC value determined on suspended cells [13]. On the other hand, salvipisone was shown to 
prevent the adhesion of S. aureus (ATCC 29213) at a concentration of 60 μM, which coincided with its 
bacteriostatic effects, measured by MIC values [14]. Thus, selectivity of compound 2 is better than that 
of the only two anti-biofilm abietane-type diterpenes reported in the literature so far.  
2.3. Non-Specific Cytotoxicity on Mammalian Cells 
Prior research on resin acids had raised concerns on the possible occurrence of cytotoxicity in 
mammalian cells. For instance, abietic acid had been shown to be toxic to pulmonary epithelial cells, 
causing cell lysis [25]. To exclude the possibility that 1–3 could be exerting anti-biofilm effects due to 
non-specific cytotoxicity (i.e., due to a membranolytic effect), cytotoxicity assays were performed. 
These cell lines (HL, HepG2 and GT1-7) were selected for these studies as they represent three distinct 
cellular phenotypes, originating from human respiratory tract, human hepatocytes and mouse 
hypothalamus, respectively. Together, they offer a good predictive assessment of possible cytotoxic 
effects that may occur upon exposure to compounds 1–3. After 24 h, concentrations of 1 and 3 above 
25 and 5 µM respectively were shown to cause more than 50% cell death. In contrast, the three cell 
lines tolerated 2 better, and estimated LC50 values were (between parenthesis, 95% confidence 
intervals): 106.4 µM (99.6–113.7 µM) for HL cells; 153.0 µM (139.9–167.3 µM) for HepG2 cells, and 
176.3 µM (165.4–188.0) for GT1-7 neurons (Table 3). Compound 2, (+)-dehydroabietic acid, has been 
reported to exert a potent gastroprotective effect in vivo, and LC50 values in human lung fibroblasts 
(MRC-5) and a human epithelial gastric cell line (AGS) have been estimated to be of 171 and 95 μM, 
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respectively [26], in agreement with the results reported here. Compound 2 was then selected for 
follow-up studies.  
Table 3. Biocompatibility index (BI) for compound 2. Three different values were 
calculated based on the cytotoxicity results registered in three different cell lines (LC50), 
and the concentration of compound 2 causing a 3-log reduction in the post-exposure  
anti-biofilm assay (140 μM, corresponding to 42.1 mg/L).  
Cell line Cytotoxicity (LC50) μM [mg/L] Biocompatibility Index * 
GT1-7 176.3 [52.9] 1.3 
HepG2 153.0 [45.9] 1.1 
HL 106.4 [31.9] 0.76 
* For the BI calculations, values in mg/L were used.  
2.4. Anti-Biofilm Killing Efficacy of Compound 2 and Biocompatibility Index 
The killing efficacy of compound 2 was studied by assessing the actual concentration of biofilms 
left on the wells upon treatment with the compound and calculating the log R parameter, as in [27] 
(Figure 1).  
Figure 1. Killing anti-biofilm efficacy of compound 2 measured using Log Reduction (Log R), 
prior to biofilm formation (black bars) or post-biofilm formation (grey bars). As an insert, 
fluorescence microscopy images of 18 h S. aureus biofilms treated (or not) with 2 are 
shown. Fluorescence signal (G/R fluorescence ratios) calculated on replicate wells, are 
shown in each image. 
 
Viable bacterial concentration recovered from the untreated biofilm wells was 108 CFU/mL  
(1.25 × 107 CFU/cm2) and their viability was illustrated by the prevalence of green fluorescence 
emission in FM imaging (insert, Figure 1). As expected, for the preventive effect, compound 2 at  
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60 µM (corresponding to IC90) caused 1-log biofilm reduction, but a moderate concentration of  
100 µM resulted in a 3-log reduction and a full 8-log reduction was measured at 400 µM, indicative of 
the highest possible killing efficacy that resulted in a complete absence of viable colonies in the 
treated-biofilms. Compound 2 decreased also bacterial viability on existing biofilms in a 
concentration-dependent manner. At moderate concentrations (80; 100 µM), a 2-log reduction was 
detected. A concentration of 140 µM caused a 3-log reduction, indicative of 99.9% killing of the viable 
cells residing on the biofilms, and higher concentrations (200; 400 µM) caused a significant 4-log 
reduction in viable counts. In contrast, penicillin only caused 1-log reduction at 400 µM in 18 h 
biofilms. In immunotolerant biofilm infections, a reduction of the biofilm burden of 3-log is highly 
desirable to assist the immune system in clearing the remaining pathogens in vivo. In parallel, upon 
biofilms exposure to 2 at 100 and 400 μM, a progressive shift towards red fluorescence (indicative of 
uptake of propidium iodide by dying cells) was registered with a decrease in the G/R fluorescence ratio 
to 0.72 ± 0.10 and 0.43 ± 0.06 from 2.75 ± 0.43 in untreated biofilms (insert, Figure 1). This dramatic 
decrease of the G/R ratio caused by the addition of higher concentrations of compound 2 is in 
agreement with its good killing capacity (log R results). In contrast, in biofilms that were treated with 
penicillin at 400 μM, the G/R fluorescence ratio decreased only to 1.54 ± 0.17, confirming that this 
concentration causes roughly only a 50% reduction of biofilms viability on 18 h biofilms.  
To quantitatively assess the relevance of the anti-biofilm killing efficacy of compound 2 in 
comparison to the cytotoxicity results, the Biocompatibility Index (BI) was calculated (Table 3).  
BI, as originally defined in [28], is a dimensionless parameter resulting from the ratio of the in vitro 
cytotoxicity values (in this case, half-lethal concentrations, LC50) to the concentration of the compound 
causing a 3-log reduction in the viable counts of suspended bacteria. Here, we applied this calculation 
to assess the impact of the anti-biofilm activity of compound 2. The original definition presented  
in [28] was proposed for antiseptic agents that are expected to act within a very short exposure time. 
Thus, the authors used a 30-minute exposure time to the biocides for both cytotoxicity and antibacterial 
assays. However, in our assays, a 24-h exposure time has been used in both cases, which is the typical 
in vitro exposure time used for antibacterial assessment of antibiotics. Additionally, because the 
concentrations at which anti-biofilm compounds can act on existing biofilms are of more clinical 
relevance instead of those preventing their formation, we selected the concentration of compound 2 
causing a 3-log reduction in the post-exposure paradigm (140 μM) according to the results of the log R 
assay (Figure 1). Although the choice of the concentration of 2 at which a 3-log reduction is achieved 
during the pre-exposure assay (100 μM) would have resulted in a better BI value, the authors felt that it 
would have not been an accurate reflection of the most challenging scenario that should be tackled in vivo.  
The BI value of compound 2 was higher than 1 when 2 out of the 3 cell lines were used for the 
calculations, which is indicative of an adequate combination of an effective anti-biofilm activity with a 
low cytotoxicity. In the case of the HL cells, the lower LC50 value registered caused the BI to be lower 
than 1. For compound 2 to be developed into a drug, the BI values should obviously be favorable in all 
cases to minimize the risks of toxic effect on the host organisms. However, the usefulness of this 
compound as a chemical tool in basic biofilms studies is not by any means compromised with these 
results. Calculations of BI index are not commonly seen within reports of anti-biofilm molecules, but 
this represents a useful parameter for quick exclusion of undesired toxic scaffolds or weak hits in early 
stage of development of anti-biofilm molecules. 
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2.5. Mechanistic Insights into Anti-Biofilm Activity of Compound 2 
The question then arose as to which stage during the biofilm formation process, compound 2 would 
be more prone to act, and to elucidate this we performed mechanistic studies. The first experiment was 
designed to study the possible effects of compound 2 on the bacterial attachment to the polystyrene 
surface of microtiter well plates, as this is the first recognized step leading to biofilm establishment [29]. 
Bacteria were let to attach for 1 h in the presence or absence of compound 2, and after 1 h, the 
planktonic cells were removed and replaced with fresh culture media for additional 17 h. The amount 
of cells that attached during the first hour was enough to ensure biofilm formation in fresh media after 
17 h, and similar growth was in fact observed when compared to normal experimental conditions 
during 18 h without media refreshment (results not shown). For this test, compound 2 was tested at  
30 and 60 µM (both concentration values are sub-MIC). Exposure to compound 2 during the 
attachment phase resulted in 97.5% ± 3.4% (at 30 µM) and 91.3% ± 18.7% (at 60 µM) of viable 
biofilms, thus no anti-biofilm activity was detected. This suggests that compound 2 does not likely 
target the initial bacterial attachment phase.  
Next, the effects of 2 were studied on the proliferation and maturation phases (Figure 2). After 
initial attachment, bacterial cells start to divide and transition into biofilms, and this is also often 
referred to as the proliferation or accumulation phase. If conditions are suitable, maturation takes 
place, in which a plateau phase is achieved with decreased metabolic activity. The kinetics of biofilm 
formation (Figure 2, filled diamonds) showed that after the attachment phase (first hour), an active 
accumulation phase followed (up to five hours), with a plateau phase that was reached after six hours. 
Due to the presence of biofilms on different growth phases, a higher concentration of 2 (60 µM) was 
added in this trial (Figure 2, unfilled squares). At time zero, the concomitant addition of 2 and bacteria 
caused 90% of biofilm inhibition, corresponding to preventive effect. After that, the anti-biofilm 
activity of 2 was maintained at high levels (around 70% inhibition) even if 2 was added up to five 
hours after biofilm formation had started, during the accumulation phase. This stage is characterized 
by cell-to-cell adhesion, proliferation (increase in cellular density of the biofilm) and EPS production, 
which could all be targeted by this molecule. However, if present only during the plateau, its  
anti-biofilm activity decreased.  
Since these effects of 2 were detected at a sub-MIC concentration (60 µM), it seems likely that this 
molecule targets events that are specific to the biofilm accumulation stage, such as the quorum-sensing 
(QS) process. However, because this compound can affect bacterial growth at higher concentrations, it 
is probable that it also modulates off-target (secondary) processes not specific to the biofilm lifestyle. 
For instance, 14-isopropylpodocarpa-8,11,13-trien-13-ol (totarol) which has a tricyclic skeleton similar 
to 2, has been shown to display antibacterial effects via the inhibition of the oxidation of NADH and 
NADH related reductases [30]. In the case of 2, the prevailing effect (anti-biofilm or antibacterial) is 
likely to be influenced by the concentrations reaching the biofilms or the affinities on the actual target 
molecules, among others. A combination of anti-biofilm and antibacterial actions has been similarly 
described for 4-epi-pimaric acid [13], which was shown to inhibit active S. mutans biofilm accumulation 
phase without affecting the adherence of the cells to polystyrene plates. This compound was shown to 
inhibit the synthesis of glucan (from the Streptococcus mutans matrix) but it also permeabilizes 
membranes, leading to biofilm killing and, at higher concentrations, to antibacterial effects [13].  
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Figure 2. Inhibitory effects registered by the addition of 2 (unfilled squares) at different 
time-points, corresponding to different phases of biofilm growth by ATCC 25923 in  
96-well plates (filled diamonds).  
 
Across all the studies performed in this study, biofilm formation was measured in the bare 
polystyrene surface of the microtiter well plates. However, in practice, biofilms are frequently formed 
on substrates (i.e., catheters or other medical devices) that are conditioned with adhesive matrix 
proteins, such as fibrinogen, fibronectin or collagen. Consequently, testing the activity on biofilms 
formed on preconditioned surfaces is particularly relevant, from a clinical perspective. To mimic such 
scenario in vitro, biofilms were formed on polystyrene plates that were coated with fibrinogen and 
fibronectin, which are two typically abundant proteins in host cells and to which S. aureus contains 
several receptors [31–33]. Biofilm formation was quantitatively similar in protein-coated and uncoated 
polystyrene plates, within the whole concentration range tested (results not shown). The same 
inhibitory effect (around 50%) was registered for 2 (at 30 µM, corresponding to IC50 in the pre-exposure 
assay) in protein-coated or uncoated plates. For instance, in the presence of fibrinogen or fibronectin  
(5 µg/mL), viability in 2-treated biofilms was 57.8% ± 7.5% and 52.3% ± 1.2%, respectively.  
3. Experimental Section 
3.1. Compounds Collection—Chemistry 
A collection of ten diterpenes from the genus Picea and their derivatives was studied (Table 1), 
including the commercially available (+)-dehydroabietic acid and (+)-dehydroabietylamine as well as 
eight other semi-synthetic derivatives. Detailed information is included in the Appendix.  
3.2. Biofilm Formation Assay 
Model biofilm forming bacterium was S. aureus (ATCC 25923). Biofilm formation assay was 
conducted as previously described by our group [34]. Briefly, exponentially growing bacteria were 
added to flat-bottomed 96-well microplates (Nunclon ∆ surface, Roskilde, Denmark) at the initial 
concentration of 106 CFU/mL (200 µL) and biofilms were formed at 37 °C, 200 rpm for 18 h in tryptic 
soy broth (TSB, Fluka Biochemika, Buchs, Switzerland).  
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3.3. Compounds Exposure  
Anti-biofilm effects of the compounds (in 2% DMSO) were examined prior to biofilm and  
post-biofilm formation. In the first case, compounds and bacterial suspension were added 
simultaneously and effects were examined after incubation at 37 °C, 200 rpm for 18 h. In the second 
case, biofilms were formed during 18 h (37 °C, 200 rpm), compounds were added and plates were 
incubated for 24 h at 37 °C, 200 rpm. Untreated biofilms (only exposed to culture media), cell-free 
wells containing only TSB and wells containing biofilms and 2% of DMSO were included as controls. 
Penicillin G, used as control antibiotic in all experiments, was prepared in Müeller-Hinton Broth 
(MHB). Initial screening of the chemical collection was conducted at a final compound concentration 
of 400 µM. Anti-biofilm potencies of 1–3 were measured within a concentration range of  
1 nM–400 µM. Penicillin was tested at 400 µM unless indicated otherwise.  
3.4. Quantification of Biofilms 
Biofilms viability was measured with a redox dye, resazurin (Sigma-Aldrich, St. Louis, MO,  
USA) [22]. Planktonic suspension was removed, resazurin 20 µM was added and plates were 
incubated (200 rpm, 20 min, RT, darkness) followed by fluorescence measurement (λex = 570 nm;  
λem = 590 nm) using Varioskan reader (Thermo Fisher Scientific, Vantaa, Finland). Total bacterial 
biomass was assessed with crystal violet dye (Sigma-Aldrich, St. Louis, MO, USA). Since resazurin is 
not toxic to the cells, the crystal violet assay was conducted right after finishing the viability assay as 
optimized in [8]. The biomass assay was performed in automated conditions [34], combining a Biomek 
3000® liquid handling workstation (Beckman Coulter Inc., Fullerton, CA, USA) with a Multidrop® 
Combi dispenser (Thermo Fisher Scientific, Vantaa, Finland). The absorbance of crystal violet-stained 
biofilms (λ = 595 nm) was measured using Varioskan plate reader.  
3.5. Bacteriostatic Effect on Planktonic Cells 
Exponentially grown S. aureus suspensions (106 CFU/mL) were added to the plates and incubated 
with serial dilutions of compounds 1–3 at 37 °C for 18 h, coinciding with the time used in the biofilm 
formation studies. After incubations, the minimal concentrations of the compounds causing no turbidity 
were recorded as the MIC values. MIC values were also recorded for the control antibiotic (penicillin 
G). Quantitative absorbance measurements (λ = 620 nm) were done using Varioskan plate reader.  
3.6. Cytotoxicity Assessment on Mammalian Cells 
Human lung (HL), HepG2 (ATCC HB-8065) and GT1-7 neurons were grown as in [35]. Cell 
suspensions (4 × 105 cells/mL) were added into plates and incubated at 37 °C for 24 h. Then, 20 µL of 
culture media was replaced with a similar volume of solutions containing the compounds at different 
concentrations (1 nM–400 µM) and plates were incubated for another 24 h at 37 °C. Then, culture 
media was replaced with a solution of resazurin (20 µM) for HL and HepG2 cells and 25 µM for  
GT1-7 cells, and they were incubated for 2 h at 37 °C. Reduced resazurin fluorescence was measured 
as described in 4.4. Untreated cells, cell-free wells, as well as cells exposed to 0.5% DMSO (solvent 
control), were all included.  
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3.7. Studies on the Anti-Biofilm Activity of Compound 2 
3.7.1. Determination of Log Reduction (Log R) 
Log R was estimated as in [27], using viable cell counts in tryptic soy agar (TSA) plates. At the end 
of the exposure to 2, suspensions were removed and biofilms were scraped off the wells, twice. The 
resulting suspension was mixed vigorously and sonicated for 5 min in order to disperse bacterial 
aggregates. To confirm that all biofilms have been recovered, the scrapped wells were stained with 
resazurin (as in 4.4). Serial dilutions were spread onto TSA plates and incubated at 37 °C overnight. 
Log R was determined by subtracting the log of the bacterial concentrations in treated samples from 
the ones quantified in untreated biofilms.  
3.7.2. Imaging with Wide-Field Fluorescence Microscopy (FM) 
Viability kit (LIVE/DEAD® BacLight™, Eugene, OR, USA), containing SYTO 9 and propidium 
iodide was used. Biofilms were formed as in 4.2, followed by the addition of 2 (100; 400 µM) for 24 h. 
Planktonic cells were then removed. The probes mixture (SYTO 9 5 µM; propidium iodide 30 µM) 
was added (6 µL) followed by incubation (15 min, RT, darkness). FM was performed with an Axiovert 
200 M inverted microscope (Carl Zeiss MicroImaging, Jena, Germany) with a 40×/0.6 LD-Plan 
Neofluar objective and using FITC and TRITC filter sets for SYTO 9 and propidium iodide, 
respectively, as in [8]. Images were acquired by using a Hamamatsu ORCA-ER camera (Hamamatsu 
Photonics K.K., Hamamatsu, Japan) with Axiovision Release 4.8 software (Carl Zeiss Microimaging, 
Jena, Germany). These experiments were performed at the Cell Imaging Core, Turku Centre for 
Biotechnology, Finland. The fluorescent signal generated by the mixture of probes in this experiment 
was quantified in parallel by adding 200 µL of the probes mixture (SYTO 9 5 µM and propidium 
iodide 30 µM) to 96-well plates. The measurement was conducted (λex = 485 nm and λem = 530 nm for 
SYTO 9 and λem = 630 nm for propidium iodide) using a Varioskan multimode plate reader.  
3.7.3. Effect on Initial Bacterial Adhesion 
S. aureus suspensions (106 CFU/mL) were added to the plates in the presence or in the absence of 2 
(30 µM and 60 µM). Cells were let to attach for 1 h prior to removing the planktonic phase and 
replacing it with fresh TSB. After that, biofilms were let to form for additional 17 h before 
quantification with resazurin, as in 4.4.  
3.7.4. Effects on Biofilm Proliferation or Maturation Phases 
To first confirm the time-course of biofilm formation, untreated bacterial samples (106 CFU/mL) 
were added to the plates, and viability was measured at various time points up to 18 h. Then, in another 
set of samples, compound 2 (60 µM) was added at various time points after adding the suspended 
bacteria into the plates. The biofilm viability was quantified with resazurin at the end of the 18 h (as 
described in 4.4), and compared to samples that were only exposed to culture media at similar time-points.  
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3.7.5. Bacterial Adhesion in the Presence of Host Proteins 
Plates were pre-treated with various concentrations (1, 2, 5 µg protein/mL) of fibrinogen and 
fibronectin (in sterile water), at 4 °C for 24 h, as described earlier [19]. After that, bacterial 
suspensions (106 CFU/mL) and compound 2 (30 µM) were added and biofilms were formed for 18 h. 
Anti-biofilm activity of 2 was measured with the resazurin assay (4.4). 
3.8. Statistical Analysis and Data Processing 
At least four replicates per treatment were included in each plate, and two separate experiments 
(biological replicates) were always run. Anti-biofilm activities were expressed as inhibition 
percentages of the untreated biofilms [Equation (1)]. Potencies of the anti-biofilm effects (IC50) were 
calculated from at least 14 concentration points via a non-linear regression analysis (sigmoidal  
dose-response with variable slope) and the result is presented with 95% confidence intervals. In the 
case of the cytotoxicity studies, half lethal concentrations (LC50) were calculated from viability 
percentages of untreated controls with Equation (2), using also a similar non-linear regression analysis. 
Below, μmax, and μmin represent the means (average) of the signals (fluorescence of the reduced 
resazurin, or absorbance of the crystal violet stained biofilms) recorded in untreated biofilms and TSB 
controls, respectively.  
Inhibition % = [(µmax − µtreated well)/(µmax − µmin)] × 100% (1)
Viability % = (µtreated well/µmax) × 100% (2)
The Biocompatibility Index of compound 2 was calculated according to [28], as the ratio of the 
LC50 value obtained for each tested cell line and the concentration producing 3-log reduction on the 
viable colonies of biofilms (post-exposure paradigm). In both trials, a similar 24-h exposure to 
compound 2 was used, to record a more meaningful BI value. A paired t test (two-tailed) was used for 
the paired comparison in 4.7.5. p < 0.05 was regarded as statistically significant. All data processing 
and statistical analysis was done with Microsoft Excel 2010 software and GraphPad Prism version 5.0 
for Mac, GraphPad Software (San Diego, CA, USA), respectively.  
4. Conclusions  
The three abietane-type diterpenes presented herein constitute readily accessible anti-biofilm 
compounds (in terms of availability and chemical stability). In particular, compound 2 can be obtained 
from various commercial sources. In contrast, other abietanes such as salvipisone and 4-epi-pimaric 
are not commercially available, and limited amounts have been isolated from plant sources. Moreover, 
the anti-biofilm potency of compound 2 refers not only to its ability to prevent bacterial colonization, 
but also to the inhibition of existing biofilms, specifically by acting during the biofilm accumulation 
stage. A predictive assessment of the therapeutic usefulness made via the calculation of the 
Biocompatibility Index, showed that compound 2 combines high anti-biofilm efficacy with low 
cytotoxicity (BI > 1) except for one of the three tested cell lines for which the BI value was not 
favorable. (+)-Dehydroabietic acid therefore holds great promise as a molecular probe for in vitro 
biofilms studies, and can be used as a potent positive control. Keeping in mind all the elements 
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discussed above, this compound could also serve as well as an inspirational model for the development 
of potent anti-biofilm drug candidates, but cytotoxicity studies and calculations of the BI values of new 
chemical derivatives, should be performed early on. Disturbance of flow-grown biofilms by 2 has been 
further recorded using Bioflux technology (Supplementary Video). Ongoing studies in our laboratory 
are presently focused on deconvoluting the possible targets of 2, not only to clarify its mechanism of action, 
but with the aim of expanding our drug discovery strategies towards target-based approaches as well.  
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Appendix 
Chemistry 
All starting synthetic reagents were acquired from Wako Pure Chemical Industries (Osaka, Japan), 
Fluka (Buchs, Switzerland), and Sigma-Aldrich (St. Louis, MO, USA). Toluene and diethyl ether were 
distilled from sodium/benzophenone ketyl. All reactions in anhydrous solvents were performed in 
flame-dried glassware under an inert atmosphere of dry argon. The progress of chemical reactions was 
monitored by thin-layer chromatography on silica gel 60-F254 plates (Merck, Darmstadt, Germany) 
using phosphomolybdic acid stain (10% by weight in EtOH) or ninhydrin stain (1.5% by weight in 
EtOH). Flash SiO2 column chromatography was performed with a Merck silica gel 60 (230–400 mesh) 
or with a Biotage High-Performance Flash Chromatography Sp4-system (Uppsala, Sweden) using a 
0.1-mm pathlength flow cell UV-detector/ recorder module (fixed wavelength: 254 nm), 12-mm or  
25-mm flash cartridges. Purity of all tested compounds was higher than 95% (GC-MS). 1H-NMR and 
13C-NMR spectra were recorded on a Varian Mercury 300 MHz spectrometer (Varian, Palo Alto, CA, USA) 
as solutions in deuterochloroform, dimethyl sulfoxide-d6, and acetone-d6 (Sigma-Aldrich, Schnelldorf, 
Germany). GC-MS system consisted of a 5890A gas chromatograph and 5970 mass selective detector 
(Hewlett-Packard, Palo Alto, CA, USA); GC-MS spectra were analyzed with HP Chemstation program. 
Melting points were measured with an Electrothermal IA 9100 apparatus and are uncorrected. 
Nordehydroabietylamine (1) 
For preparing nordehydroabietylamine (compound 1), a mixture of compound 2 (0.304 g,  
1.00 mmol), diphenylphosphoryl azide (0.275 g, 1.00 mmol, 1 equiv) and triethylamine (0.101 g,  
1.00 mmol, 1 equiv) in anhydrous toluene (10 mL) was stirred, at reflux, for 24 h. Benzyl alcohol 
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(0.541 g, 5.00 mmol, 5 equiv) was added to the reaction mixture and refluxing was continued for 24 h. 
GC-MS analysis showed the molecular ion [M+] of the formed isocyanate (m/z 297) while LC-MS 
analysis showed that of the formed carbamate (m/z 405). The burgundy mixture was concentrated 
under reduced pressure and the resulting crude product was used. After removal of air from the flask 
by suction, the crude carbamate (0.406 g, 1.00 mmol) was hydrogenated (H2, 3 atm) at room 
temperature in the presence of Pd/C (10%, 0.04 g), in methanol (10 mL), for 16 h. The catalyst was 
then removed by filtration through a pad of Celite 545 and washed with methanol. The filtrate was 
concentrated under reduced pressure. The resulting mixture was extracted with dichloromethane  
(3 × 10 mL). The combined organic layers were dried with anhydrous Na2SO4, filtrated and evaporated 
to dryness to give a pale yellow crude solid. The crude product was purified by flash column 
chromatography (Biotage MPLC, CHCl3/MeOH, (10:1) to give a white solid (0.23 g, 85%). Rf 0.02  
(n-hexane/EtOAc 2:1); 1H NMR (300 MHz, CDCl3) δ 8.31 (s, 2H), 6.98 (d, J = 8.3 Hz, 1H), 6.89 (d,  
J = 8.3 Hz, 1H), 6.82 (s, 1H), 2.94–2.58 (m, 2H), 2.13 (d, J = 12.4 Hz, 1H), 1.99 (dd, J = 49.8, 12.1 Hz, 
3H), 1.51 (s, 4H), 1.28 (s, 4H), 1.25 (s, 3H), 1.21 (s, 2H), 1.07 (s, 3H), 0.98–0.47 (m, 2H); 13C NMR 
(75 MHz, CDCl3) δ 152.80, 145.89, 134.78, 127.13, 124.73, 124.00, 57.39, 48.07, 38.07, 37.24, 33.74, 
31.79, 29.88, 25.07, 22.86, 19.62, 19.16, 18.36, 14.32; GC-MS m/z 271 [M+] (tR = 12.6 min). 
(+)-Dehydroabietic acid (2) 
(+)-Dehydroabietic acid (compound 2) was commercially purchased (Wako Pure Chemical 
Industries, Ltd, 85%–90%) and recrystallized from n-hexane and ethyl acetate to give white crystals.  
Rf 0.62 (n-hexane/EtOAc 2:1); mp 168–171 °C; 1H NMR (300 MHz, CDCl3) δ 11.64 (s, 1H), 7.17 (d,  
J = 8.2 Hz, 1H), 7.01 (d, J = 8.2 Hz, 1H), 6.90 (s, 1H), 3.01–2.78 (m, 2H), 2.32 (d, J = 12.7 Hz, 1H), 
2.26 (dd, J = 12.4, 2.1 Hz, 1H), 1.96–1.56 (m, 6H), 1.56 (m, 3H), 1.30 (s, 3H), 1.25 (s, 3H), 1.23 (s, 
3H), 1.22 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 185.36, 146.95, 145.93, 134.89, 127.10, 124.30, 
124.08, 47.63, 44.80, 38.12, 37.07, 36.95, 33.67, 30.20, 25.33, 24.18, 21.97, 18.74, 16.41; GC-MS m/z 
300 [M+] (tR = 8.17 min); IR (KBr, cm−1): 3100 br m, 2958 br m, 2931, 2869, 1694 C=O, 1459, 1280, 
1190, 949, 819. 
(+)-Dehydroabietylamine (3) 
(+)-Dehydroabietylamine (compound 3) was purified by a reported crystallization method [33] with 
slight modifications. The crude (+)-dehydroabietylamine (Sigma-Aldrich, St. Louis, MO, USA) was 
estimated to have a purity of approx. 60% by GC-MS. A solution of glacial acetic acid (7.5 mL) in 
toluene (75 mL) was added dropwise over a period of 40 min to a cooled (0 °C) solution of crude 
compound (35.0 g, 0.13 mol) in toluene (200 mL). The mixture was stirred at 10 °C for 2 h, and the 
resulting precipitate was collected under reduced pressure, washed with cold toluene (75 mL) and 
dried. The white solid was recrystallized from toluene (150 mL) to yield dehydroabietylammonium 
acetate (37.5 g, 70%) as fine, white needles, mp 141–143 °C, [α]D21 + 31 (c 2.5, MeOH, mp 141–143.5 °C, 
[α]D25 + 30.5) [33]. Dehydroabietylammonium acetate (25.0 g, 0.145 mmol) was dissolved in warm 
water (150 mL) and cooled to room temperature before adding 1 M sodium hydroxide (20 mL). The 
resulting solution was stirred for 1 h before extracting the free amine into diethyl ether (250 mL). The 
organic solution was dried with anhydrous sodium sulphate, filtered and evaporated to dryness 
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Residual solvent was removed in vacuo to yield (+)-dehydroabietylamine (39.7 g, 96%) as a yellow 
oil, which was washed with diethyl ether to give a white solid. Rf 0.13 (n-hexane/EtOAc 2:1);  
mp 41–43 °C, [33], mp 41 °C); 1H NMR (300 MHz, CDCl3) δ 7.19 (d, J = 8.2 Hz, 1H), 7.00 (dd,  
J = 8.2, 2.0 Hz, 1H), 6.90 (s, 1H), 2.98–2.77 (m, 3H), 2.61 (d, J = 13.3 Hz, 1H), 2.40 (d, J = 13.3 Hz, 
1H), 2.29 (dt, J = 12.0, 3.1 Hz, 1H), 1.87–1.61 (m, 5H), 1.52 (dd, J = 10.6, 4.1 Hz, 1H), 1.43 (d,  
J = 4.1 Hz, 1H), 1.34 (td, 14.7, 4.1 Hz, 3H), 1.24 (br. s, 3H), 1.23 br. s, 3H), 0.89 br. s, 3H); 13C NMR 
(75 MHz, CDCl3) δ 147.66, 145.70, 134.88, 126.98, 124.43, 124.00, 54.03, 45.04, 38.73, 37.57, 37.39, 
35.39, 33.62, 30.36, 25.44, 24.19, 24.17, 18.95, 18.82; IR (KBr, cm−1): 3393.5 (N–H), 2956, 2923, 
2864, 1611, 1560, 1497, 1457; GC-MS m/z 285 [M+] (tR = 6.81 min); LC-MS m/z 286.3 [M + H]+  
(tR = 15.4 min, 98.7%). 
Compounds 4–10 were synthesized from compound 3 via the isocyanate method [36], with 
isocyanate (1.1 eq), in tetrahydrofuran, at r.t. for 24 h. 
1-[4-(Benzyloxy)phenyl]-3-[[(1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-
octahydrophenanthren-1-yl]methyl]urea (4) 
Rf 0.53 (n-hexane/EtOAc, 2:1); mp 141–143 °C; 1H NMR (300 MHz, DMSO-d6) δ 8.16 (s, 1H),  
7.55–6.50 (m, 10H), 6.01 (s, 1H), 5.01 (s, 2H), 3.32 (d, J = 1.6 Hz, 2H), 3.13 (dd, J = 13.4, 5.8 Hz, 
1H), 2.96–2.61 (m, 3H), 2.26 (d, J = 12.4 Hz, 1H), 2.02–0.50 (m, 18H); 13C NMR (75 MHz,  
DMSO-d6) δ 155.43, 152.75, 147.09, 144.93, 137.36, 134.50, 133.99, 128.35, 127.68, 127.59, 126.40, 
124.10, 123.55, 118.87, 114.95, 69.38, 49.06, 43.96, 38.10, 37.12, 36.94, 35.39, 32.88, 29.73, 25.13, 
23.94, 18.85, 18.26; 13C NMR DEPT (75 MHz, DMSO-d6) δ 128.36, 127.69, 127.60, 126.41, 124.11, 
123.56, 118.88, 114.96, 69.38, 49.06, 43.96, 38.10, 32.88, 29.73, 25.13, 23.95, 18.86, 18.27; IR (KBr, 
cm−1): 3343 br m N–H, 2925 br m, 1645 C=O, 1564, 1511, 1223, 826; LC-MS (508.31) m/z 509.3  
[M + H]+ (tR = 22.1 min, 96.2%).  
1-(3-Chlorophenyl)-3-[[(1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-
octahydrophenanthren-1-yl]methyl]urea (5) 
Rf 0.40 (n-hexane/EtOAc, 2:1); mp 102–104 °C; 1H NMR (300 MHz, Acetone-d6) δ 8.05 (s, 1H),  
7.79–7.66 (m, 1H), 7.25–7.09 (m, 3H), 6.99–6.92 (m, 1H), 6.89 (m, 1H), 6.86 (s, 1H), 5.89 (s, 1H),  
3.36–3.25 (m, 1H), 3.00 (dd, J = 13.8, 6.4 Hz, 1H), 2.87–2.68 (m, 3H), 2.28 (dt, J = 15.6, 7.9 Hz, 1H), 
2.00–1.90 (m, 1H), 1.87–1.54 (m, 3H), 1.52–1.25 (m, 3H), 1.20 (s, 6H), 1.17 (s, 3H), 0.94 (s, 3H); 13C 
NMR (75 MHz, Acetone-d6) δ 156.03, 148.17, 146.18, 143.13, 135.60, 134.71, 130.77, 127.55, 
124.99, 124.49, 121.79, 118.45, 116.90, 50.46, 45.44, 39.31, 38.31, 38.12, 36.67, 34.26, 30.90, 25.67, 
24.38, 19.58, 19.36; IR (KBr, cm−1): LC-MS (438.24) m/z 439.3 [M + H]+, 461.3 [M + Na]+ (tR = 22.4,  
min, 95.8%). 
1-[[(1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]methyl]-3-(4-
phenoxyphenyl)urea (6) 
Rf 0.64 (n-hexane/EtOAc, 2:1); mp 162–164 °C; 1H NMR (300 MHz, DMSO-d6) δ 8.36 (s, 1H),  
7.32 (m, 4H), 7.13 (d, J = 8.2 Hz, 1H), 7.09–7.00 (m, 1H), 6.90 (t, J = 9.4 Hz, 5H), 6.82 (s, 1H), 6.08  
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(t, J = 6.0 Hz, 1H), 3.27–3.05 (m, 1H), 2.77 (m, 5H), 2.25 (d, J = 12.6 Hz, 1H), 1.72 (m, 7H), 1.13 (s, 
6H), 1.11 (s, 3H), 0.85 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 157.87, 155.32, 149.68, 147.08, 
144.94, 136.75, 134.49, 129.82, 126.41, 124.09, 123.56, 122.51, 119.88, 118.89, 117.31, 49.04, 43.97, 
38.10, 37.14, 36.94, 35.38, 32.88, 29.73, 25.12, 23.95, 18.84, 18.31; IR (KBr, cm−1): 3334, 2957, 2924.0, 
2866, 1645, 1562, 1488, 1226, 1089, 832; LC-MS (496.31) m/z 497.3 [M + H]+ (tR = 22.3 min, 96.8%). 
1-(4-Chloro-2-phenoxyphenyl)-3-[[(1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-
octahydrophenanthren-1-yl]methyl]urea (7) 
Rf 0.88 (n-hexane/EtOAc, 2:1); mp 240–243 °C; 1H NMR (300 MHz, DMSO-d6) δ 8.37 (s, 1H), 
8.34 (d, J = 2.5 Hz, 1H), 7.34 (t, J = 8.0 Hz, 2H), 7.13 (d, J = 8.1 Hz, 2H), 7.07–6.91 (m, 3H), 6.87 
(dd, J = 8.6, 2.6 Hz, 2H), 6.83 (s, 1H), 6.72 (d, J = 8.6 Hz, 1H), 4.01 (s, 1H), 3.19 (d, J = 13.7 Hz, 1H), 
2.78 (m, 4H), 2.25 (d, J = 12.2 Hz, 1H), 1.72 (d, J = 71.2 Hz, 5H), 1.31 (m, 4H), 1.14 (s, 6H), 1.13 (br. 
s, 3H), 0.86 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 156.24, 154.94, 147.00, 144.92, 143.61, 134.41, 
133.26, 130.01, 127.39, 126.38, 124.05, 123.84, 123.53, 120.47, 118.70, 118.30, 49.27, 44.12, 38.00, 
37.06, 36.94, 35.46, 32.84, 29.72, 25.09, 23.89, 18.72, 18.33, 18.17; IR (KBr, cm−1): 3346 br m, N–H,  
2958, 2934, 2888, 1673 C=O, 1591, 1556, 1522, 1183, 860, 749, 687; LC-MS (530.27) m/z 531.2  
[M + H]+ (tR = 22.3 min). 
1-(4-Chloro-2,5-dimethoxyphenyl)-3-[[(1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-
octahydrophenanthren-1-yl]methyl]urea (8) 
Rf 0.29 (n-hexane/EtOAc, 2:1); mp 223–225 °C; 1H NMR (300 MHz, Acetone-d6) δ 8.36 (s, 1H), 
7.49 (s, 1H), 7.16 (d, J = 8.2 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 6.87 (s, 1H), 6.77 (d, J = 9.5 Hz, 1H), 
6.21 (t, J = 6.5 Hz, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 3.34 (dd, J = 13.8, 6.4 Hz, 1H), 2.97 (dd, J = 13.7, 
6.4 Hz, 1H), 2.79 (m, 5H), 2.31 (d, J = 12.9 Hz, 1H), 12.00–1.23 (m, 9H), 1.20 (s, 3H), 1.19 (s, 3H), 
1.17 (s, 3H), 0.95 (s, 3H); 13C NMR (75 MHz, Acetone-d6) δ 156.10, 150.32, 148.30, 148.10, 146.21, 
135.72, 127.59, 125.00, 124.48, 120.30, 117.67, 116.16, 113.55, 98.56, 56.99, 56.55, 50.47, 45.20, 
39.36, 38.34, 38.13, 36.68, 34.29, 30.83, 25.66, 24.37, 19.58, 19.41; IR (ATR, cm−1): 3346 br m, N–H, 
2967, 2935, 2868, 1739 C=O, 1643, 1501, 1389, 1203, 1034, 851, 767, 688; LC-MS (498.26) m/z 
499.3 [M + H]+, 521.3 [M + Na]+ (tR = 20.9 min)  
1-(tert-Butyl)-3-[[(1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-
yl]methyl]urea (9) 
Rf 0.55 (n-hexane/EtOAc, 2:1); mp 181–183 °C; 1H NMR (300 MHz, DMSO-d6) δ 7.14 (dd,  
J = 8.2, 3.3 Hz, 1H), 6.94 (d, J = 8.1 Hz, 1H), 6.83 (s, 1H), 5.60 (s, 2H), 3.33 (d, J = 1.5 Hz, 1H), 3.01 (d,  
J = 13.5 Hz, 1H), 2.73 (m, 3H), 2.25 (d, J = 12.2 Hz, 1H), 2.05–1.19 (m, 9H), 1.18 (s, 9H), 1.13 (s, 
6H), 0.81 (s, 3H). 13C NMR (75 MHz, DMSO-d6) δ 157.39, 147.15, 144.88, 134.60, 126.37, 124.12, 
123.48, 49.00, 48.84, 43.92, 38.14, 37.00, 36.92, 35.44, 32.87, 29.73, 29.28, 25.14, 23.98, 23.93, 
18.87, 18.31, 18.24; IR (KBr, cm−1): 3332 br m, N–H, 2961, 2923, 2867, 1632 C=O, 1568, 1451, 
1384, 1244, 1157, 819, 674; LC-MS (498.26) m/z 499.3 [M + H]+ (tR = 20.9 min, 99.0%). 
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1-(Benzo[d][1,3]dioxol-5-yl)-3-[[(1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-
octahydrophenanthren-1-yl]methyl]urea (10) 
Rf 0.36 (n-hexane/EtOAc, 2:1); mp 157–159 °C; 1H NMR (300 MHz, CDCl3) δ 7.31–7.22 (m, 1H), 
7.20–7.10 (m, 1H), 7.03–6.93 (m, 1H), 6.86 (dd, J = 5.6, 1.8 Hz, 1H), 6.67 (d, J = 8.2 Hz, 1H), 6.60 
(dd, J = 8.2, 2.0 Hz, 1H), 6.41–6.27 (m, 1H), 5.93–5.82 (m, 1H), 4.83 (t, J = 6.2 Hz, 1H), 3.20–3.02 
(m, 2H), 2.93–2.68 (m, 2H), 2.27 (d, J = 12.7 Hz, 1H), 1.93–1.53 (m, 4H), 1.38 (ddd, J = 15.5, 11.0, 
4.9 Hz, 2H), 1.26–0.76 (m, 11H); 13C NMR (75 MHz, CDCl3) δ 156.71, 148.32, 147.36, 145.76, 
144.91, 134.96, 132.45, 127.06, 124.39, 123.99, 116.09, 108.48, 105.24, 101.53, 50.90, 45.59, 38.65, 
37.74, 37.64, 36.35, 33.62, 30.45, 25.45, 24.18, 19.11, 18.83, 18.77; IR (KBr, cm-1): 3380 br m, N–H, 
2950, 2914, 2872, 1650 C=O, 1573, 1503, 1490, 1384, 1251, 1210, 1038, 832, 800, 667; HRMS-ESI 
(m/z): [M + H]+ calcd. 449.2804; found 449.2809. 
Supplementary Video 
Movie showing the interaction of compound 2 with S. aureus biofilms grown under flow conditions 
using Bioflux 200 (Fluxion Biosciences, CA, USA). Biofilms were grown in 48-well microplates  
(20 dyne/cm2) having microfluidic channels (370 μm × 70 μm) that were inoculated with S. aureus 
(106 CFU/mL) in 1:10 diluted TSB. Inoculation was performed by pumping at 2 dyne/cm2 for 2 s, 
from the “outlet” wells to the “inlet” wells to prevent contamination of the inlet wells. Following 1 h 
incubation for biofilm attachment (on static conditions) at 37 °C, flow was resumed at 0.4 dyne/cm2 
for 18 h from inlet to outlet wells. After biofilm formation, compound 2 (100 μM, in 1:10 TSB) was 
added into the inlet wells and flow was restarted (0.2 dyne/cm2) for additional 24 h. The video (13 s) 
was automatically created from timelapse images taken every 1 s with a coupled Transmitted Light 
Evos ×l microscope (AMG, WA, USA) with 40× objective, 15 min after starting the exposure to 2. 
References 
1. Toté, K.; Berghe, D.V.; Deschacht, M.; de Wit, K.; Maes, L.; Cos, P. Inhibitory efficacy of various 
antibiotics on matrix and viable mass of Staphylococcus aureus and Pseudomonas aeruginosa 
biofilms. Int. J. Antimicrob. Agents 2009, 33, 525–531. 
2. Melchior, M.B.; Fink-Gremmels, J.; Gaastra, W. Comparative assessment of the antimicrobial 
susceptibility of Staphylococcus aureus isolates from bovine mastitis in biofilm versus planktonic 
culture. J. Vet. Med. B 2006, 53, 326–332. 
3. Girard, L.P.; Ceri, H.; Gibb, A.P.; Olson, M.; Sepandj, F. MIC versus MBEC to determine the 
antibiotic sensitivity of Staphylococcus aureus in peritoneal dialysis peritonitis. Perit. Dial. Int. 
2010, 30, 652–656. 
4. Donlan, R.M.; Costerton, J.W. Biofilms: Survival mechanisms of clinically relevant 
microorganisms. Clin. Microbiol. Rev. 2002, 15, 167–193. 
5. Parsek, M.R.; Singh, P.K. Bacterial biofilms: An emerging link to disease pathogenesis.  
Annu. Rev. Microbiol. 2003, 57, 677–701. 
6. Worthington, R.J.; Richards, J.J.; Melander, C. Small molecule control of bacterial biofilms.  
Org. Biomol. Chem. 2012, 10, 7457–7474. 
Int. J. Mol. Sci. 2013, 14 12071 
 
 
7. Landini, P.; Antoniani, D.; Burgess, J.G.; Nijland, R. Molecular mechanisms of compounds 
affecting bacterial biofilm formation and dispersal. Appl. Microbiol. Biotechnol. 2010, 86, 813–823. 
8. Skogman, M.E.; Vuorela, P.M.; Fallarero, A. Combining biofilm matrix measurements  
with biomass and viability assays in susceptibility assessments of antimicrobials against 
Staphylococcus aureus biofilms. J. Antibiot. 2012, 65, 453–459. 
9. Phillips, M.A.; Croteau, R.B. Resin-based defenses in conifers. Trends Plant Sci. 1999, 4, 184–190. 
10. Gaspar-Marques, C.; Rijo, P.; Simões, M.F.; Duarte, M.A.; Rodriguez, B. Abietanes from 
Plectranthus grandidentatus and P. hereroensis against methicillin- and vancomycin-resistant 
bacteria. Phytomedicine 2006, 13, 267–271. 
11. Oluwatuyi, M.; Kaatz, G.W.; Gibbons, S. Antibacterial and resistance modifying activity of 
Rosmarinus officinalis. Phytochemistry 2004, 65, 3249–3254. 
12. Yang, Z.; Kitano, Y.; Chiba, K.; Shibata, N.; Kurokawa, H.; Doi, Y.; Arakawa, Y.; Tada, M. 
Synthesis of variously oxidized abietane diterpenes and their antibacterial activities against 
MRSA and VRE. Bioorg. Med. Chem. 2001, 9, 347–356. 
13. Ali, F.; Sangwan, P.L.; Koul, S.; Pandey, A.; Bani, S.; Abdullah, S.T.; Sharma, P.R.; Kitchlu, S.; 
Khan, I.A. 4-epi-pimaric acid: A phytomolecule as a potent antibacterial and anti-biofilm agent 
for oral cavity pathogens. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 149–159. 
14. Kuźma, Ł.; Rózalski, M.; Walencka, E.; Rózalska, B.; Wysokińska, H. Antimicrobial activity of 
diterpenoids from hairy roots of Salvia sclarea l.: Salvipisone as a potential anti-biofilm agent 
active against antibiotic resistant Staphylococci. Phytomedicine 2007, 14, 31–35. 
15. Esteban, J.; Molina-Manso, D.; Spiliopoulou, I.; Cordero-Ampuero, J.; Fernández-Roblas, R.; 
Foka, A.; Gómez-Barrena, E. Biofilm development by clinical isolates of Staphylococcus spp. 
from retrieved orthopedic prostheses. Acta Orthop. 2010, 81, 674–679. 
16. Lorenz, U.; Schäfer, T.; Ohlsen, K.; Tiurbe, G.C.; Bühler, C.; Germer, C.T.; Kellersmann, R.  
In vivo detection of Staphylococcus aureus in biofilm on vascular prostheses using non-invasive 
biophotonic imaging. Eur. J. Vasc. Endovasc. Surg. 2011, 41, 68–75. 
17. Donlan, R.M. Biofilm elimination on intravascular catheters: Important considerations for the 
infectious disease practitioner. Clin. Infect. Dis. 2011, 52, 1038–1045. 
18. Baveja, J.K.; Willcox, M.D.; Hume, E.B.; Kumar, N.; Odell, R.; Poole-Warren, L.A. Furanones as 
potential anti-bacterial coatings on biomaterials. Biomaterials 2004, 25, 5003–5012. 
19. Opperman, T.J.; Kwasny, S.M.; Williams, J.D.; Khan, A.R.; Peet, N.P.; Moir, D.T.; Bowlin, T.L. 
Aryl rhodanines specifically inhibit Staphylococcal and Enterococcal biofilm formation. 
Antimicrob. Agents Chemother. 2009, 53, 4357–4367. 
20. Lin, M.H.; Chang, F.R.; Hua, M.Y.; Wu, Y.C.; Liu, S.T. Inhibitory effects of  
1,2,3,4,6-penta-o-galloyl-beta-D-glucopyranose on biofilm formation by Staphylococcus aureus. 
Antimicrob. Agents Chemother. 2011, 55, 1021–1027. 
21. Lönn-Stensrud, J.; Landin, M.; Benneche, T.; Petersen, F.; Scheie, A. Furanones, potential agents 
for preventing Staphylococcus epidermidis biofilm infections? J. Antimicrob. Chemother. 2009, 
63, 309–316. 
22. Sandberg, M.E.; Schellmann, D.; Brunhofer, G.; Erker, T.; Busygin, I.; Leino, R.; Vuorela, P.M.; 
Fallarero, A. Pros and cons of using resazurin staining for quantification of viable  
Staphylococcus aureus biofilms in a screening assay. J. Microbiol. Methods 2009, 78, 104–106. 
Int. J. Mol. Sci. 2013, 14 12072 
 
 
23. Saginur, R.; Stdenis, M.; Ferris, W.; Aaron, S.D.; Chan, F.; Lee, C.; Ramotar, K. Multiple 
combination bactericidal testing of Staphylococcal biofilms from implant-associated infections. 
Antimicrob. Agents Chemother. 2006, 50, 55–61. 
24. Olson, M.E.; Ceri, H.; Morck, D.W.; Buret, A.G.; Read, R.R. Biofilm bacteria: Formation and 
comparative susceptibility to antibiotics. Can. J. Vet. Res. 2002, 66, 86–92. 
25. Ayars, G.H.; Altman, L.C.; Frazier, C.E.; Chi, E.Y. The toxicity of constituents of cedar and pine 
woods to pulmonary epithelium. J. Allergy Clin. Immunol. 1989, 83, 610–618. 
26. Sepúlveda, B.; Astudillo, L.; Rodríguez, J.A.; Yáñez, T.; Theoduloz, C.; Schmeda-Hirschmann, G. 
Gastroprotective and cytotoxic effect of dehydroabietic acid derivatives. Pharmacol. Res. 2005, 
52, 429–437. 
27. Pitts, B.; Hamilton, M.A.; Zelver, N.; Stewart, P.S. A microtiter-plate screening method for 
biofilm disinfection and removal. J. Microbiol. Methods 2003, 54, 269–276. 
28. Müller, G.; Kramer, A. Biocompatibility index of antiseptic agents by parallel assessment of 
antimicrobial activity and cellular cytotoxicity. J. Antimicrob. Chemother. 2008, 61, 1281–1287. 
29. Hall-Stoodley, L.; Costerton, J.W.; Stoodley, P. Bacterial biofilms: From the natural environment 
to infectious diseases. Nat. Rev. Microbiol. 2004, 2, 95–108. 
30. Haraguchi, H.; Oike, S.; Muroi, H.; Kubo, I. Mode of antibacterial action of totarol, a diterpene 
from Podocarpus nagi. Planta. Med. 1996, 62, 122–125. 
31. Shinji, H.; Yosizawa, Y.; Tajima, A.; Iwase, T.; Sugimoto, S.; Seki, K.; Mizunoe, Y. Role of 
fibronectin-binding proteins a and b in in vitro cellular infections and in vivo septic infections by 
Staphylococcus aureus. Infect. Immun. 2011, 79, 2215–2223. 
32. Vazquez, V.; Liang, X.; Horndahl, J.K.; Ganesh, V.K.; Smeds, E.; Foster, T.J.; Hook, M. 
Fibrinogen is a ligand for the S. aureus MSCRAMM bbp (bone sialoprotein-binding protein).  
J. Biol. Chem. 2011, doi:10.1074/jbc.M110.214981. 
33. Ganesh, V.K.; Barbu, E.M.; Deivanayagam, C.C.; Le, B.; Anderson, A.S.; Matsuka, Y.V.; Lin, S.L.; 
Foster, T.J.; Narayana, S.V.; Hook, M. Structural and biochemical characterization of Staphylococcus 
aureus clumping factor b:Ligand interactions. J. Biol. Chem. 2011, 286, 25963–25972. 
34. Sandberg, M.; Määttänen, A.; Peltonen, J.; Vuorela, P.M.; Fallarero, A. Automating a 96-well 
microtitre plate model for Staphylococcus aureus biofilms: An approach to screening of natural 
antimicrobial compounds. Int. J. Antimicrob. Agents 2008, 32, 233–240. 
35. Karlsson, D.; Fallarero, A.; Brunhofer, G.; Mayer, C.; Prakash, O.; Mohan, C.G.; Vuorela, P.; 
Erker, T. The exploration of thienothiazines as selective butyrylcholinesterase inhibitors. Eur. J. 
Pharm. Sci. 2012, 47, 190–205. 
36. Ozaki, S. Recent advances in isocyanate chemistry. Chem. Rev. 1972, 72, 457–496. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
